ASH 2013 - Chronic Myeloid Leukemia (CML) & Acute Myelogenous Leukemia (AML)

Chronic Myeloid Leukemia (CML)

ASH 2013 Abstract 4032: Dasatinib Treatment Induces Fast and Deep Responses in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006). Henrik Hjorth-Hansen et al.

Background: Dasatinib is a potent BCR-ABL1 and SRC tyrosine kinase inhibitor, which in vitro is more effective against progenitor and putative leukemia stem cells than imatinib. This may translate into deeper molecular responses in vivo. 

Conclusions: Dasatinib induced faster and deeper molecular responses than imatinib and overall responses were better in both groups than in the registration studies. Relatively high rate of serosal toxicity was observed among the dasatinib-treated patients, but this had no adverse effect on response. Upcoming studies will show if the deeper treatment responses induced by dasatinib therapy translate into increased probability of successful therapy discontinuation.

Patients treated with dasatinib achieve a faster, deeper cytogenetic and molecular response. The clinical relevance of this response needs to be determined.
— CARE Hematology Faculty

Acute Myelogenous Leukemia (AML)

AML was defined as a clonal malignancy of myeloid hematopoietic stem and progenitor cells exhibiting varying degrees of differentiation such as inappropriate proliferation, differentiation block, and impaired apoptosis. This results in the accumulation of immature, functionless cells in the bone marrow and peripheral blood.

Acute leukemia treatment remains a complex and intensive practice largely conducted at academic centers. Molecular markers have lead to better identification of high risk patients which can stratify patients for intensive transplant strategies or targeted therapies.

AML is a hematologic urgency that is usually fatal within weeks to months without chemotherapy. With treatment, however, mortality can be high due to disease or treatment-related complications.
— CARE Hematology Faculty

Novel therapy volasertib, a selective and potent polo-like kinase inhibitor, was granted Breakthrough Therapy designation from the FDA in the fall of this year. Encouraging results from a phase 2 trial have led to the initiation of the phase 3 study, POLO-AML-2, investigating volasertib in combination with LDAC, in patients aged 65 years and above with previously untreated AML who are ineligible for intensive remission induction therapy. Results of this trial are anticipated as currently many older patients are ineligible for therapy involving high doses of chemotherapy as they are often unable to tolerate.